Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Beta This is a new resource - your feedback will help us improve it.

Series: Medicare Payments for Spravato

Announced on  | Last Modified on  | Series Number: SRS-A-26-020
Status
Active
Agency
Centers for Medicare and Medicaid Services

OBJECTIVE

Spravato is a nasal spray formulation of esketamine, a Schedule III controlled substance indicated for adults with treatment-resistant depression or depressive symptoms with major depressive disorder accompanied by acute suicidal thoughts or behaviors. Medicare may cover Spravato under its medical or pharmacy benefits. Prior enforcement actions indicate that billing of Spravato may be susceptible to fraud, waste, and abuse.

There are 2 projects in this series.

ACTIVE PROJECTS IN THIS SERIES (2)

Audit of Medicare Payments for Spravato

Project OAS-25-09-149 • Announced on May 7, 2026

Data Brief: Medicare Payments for Spravato

Project OAS-26-09-093 • Announced on May 7, 2026

TIMELINE

  • May 7, 2026
    Series Number SRS-A-26-020 Assigned
  • May 7, 2026
    Projects Announced

    Audit of Medicare Payments for Spravato - OAS-25-09-149

  • Data Brief: Medicare Payments for Spravato - OAS-26-09-093

  • Today
    2 Projects In-Progress
  • Est FY2028
    Estimated Fiscal Year for Series Completion
Work Plan Type
Office of Audit Services
HHS Agencies
Centers for Medicare and Medicaid Services
Issue Areas
Managed Care Mental Health Non-institutional care Physician and Healthcare Practitioners Prescription Drug
Target Groups
-
Financial Groups
Medicare B Medicare C Medicare D